Literature DB >> 25046225

Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.

Károly Tóth1, Sreenivasulu Chintala, Youcef M Rustum.   

Abstract

The extensive lipid accumulation occurring in clear-cell renal cell carcinoma (ccRCC) results in a clear-cell cytoplasm. Hypoxia-inducible factor α (HIF-α) is constitutively expressed in many ccRCC and transcriptionally regulates >100 genes. In a recent breakthrough study, HIF-1α induced ccRCC in transgenic mice. On the basis of these findings, we developed a hypothesis that accounted for HIF-α generation of the clear-cell phenotype. The aim of the present study was to use immunohistochemical staining methods in tissue microarray to determine the extent to which the clear-cell phenotype coincided with HIF-α expression in primary and metastatic ccRCC. In addition, we studied whether the prolyl-hydroxylases (PHD2,3) play a role in promoting the elevated expression of HIF-α in tumor cells. The clear-cell phenotype was observed in all primary and metastatic cases of ccRCC examined. A total of 168 renal cell carcinomas were evaluated by immunohistochemical methods; 141 of the 168 (84%) tumors expressed HIF-α (HIF-1α and/or HIF-2α). In contrast, HIF-α was expressed in only 1 of the 23 (4%) non-ccRCCs. These data supported the hypothesis that in the majority of the tumors HIF-α expression overlapped with the clear-cell phenotype and was indicative of an HIF-α-mediated lipid accumulation. In a smaller percentage of ccRCC cases (16%), HIF-α was not detected in the tumor cells and suggested that lipid accumulation by HIF-α-lipid-independent process. PHD3 was undetectable in both primary and metastatic ccRCC cases. We concluded that the undetectable PHD3 could contribute to the higher HIF-α expression in ccRCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25046225      PMCID: PMC4184929          DOI: 10.1097/PAI.0000000000000012

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  20 in total

1.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Authors:  Jung Han Kim; Chul Won Jung; Yeon Hee Cho; Jeeyun Lee; Se-Hoon Lee; Ho Young Kim; Jinny Park; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

3.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  V H Haase; J N Glickman; M Socolovsky; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 4.  PHD2 in tumour angiogenesis.

Authors:  D A Chan; A J Giaccia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

5.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

Review 6.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

7.  Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.

Authors:  Sreenivasulu Chintala; Tanbir Najrana; Karoly Toth; Shousong Cao; Farukh A Durrani; Roberto Pili; Youcef M Rustum
Journal:  BMC Cancer       Date:  2012-07-17       Impact factor: 4.430

8.  Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts.

Authors:  Swethajit Biswas; Helen Troy; Russell Leek; Yuen-Li Chung; Ji-Liang Li; Raju R Raval; Helen Turley; Kevin Gatter; Francesco Pezzella; John R Griffiths; Marion Stubbs; Adrian L Harris
Journal:  J Oncol       Date:  2010-06-27       Impact factor: 4.375

9.  VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.

Authors:  Michelle J Nyhan; Shereen M El Mashad; Tracey R O'Donovan; Sarfraz Ahmad; Chris Collins; Paul Sweeney; Eamonn Rogers; Gerald C O'Sullivan; Sharon L McKenna
Journal:  Anal Cell Pathol (Amst)       Date:  2010       Impact factor: 2.916

10.  Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma.

Authors:  Jeanna Perman Sundelin; Marcus Ståhlman; Annika Lundqvist; Max Levin; Paolo Parini; Martin E Johansson; Jan Borén
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

View more
  8 in total

1.  Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically.

Authors:  Antoni Vilaseca; Daniel P Nguyen; Emily A Vertosick; Renato B Corradi; Mireia Musquera; Meritxell Pérez; Nicola Fossati; Daniel D Sjoberg; Ramon Farré; Isaac Almendros; Josep M Montserrat; Nicole E Benfante; A Ari Hakimi; Anders J Skanderup; Paul Russo; Antonio Alcaraz; Karim A Touijer
Journal:  World J Urol       Date:  2016-04-23       Impact factor: 4.226

2.  Sleep problems and risk of cancer incidence and mortality in an older cohort: The Cardiovascular Health Study (CHS).

Authors:  Arthur Sillah; Nathaniel F Watson; Ulrike Peters; Mary L Biggs; F Javier Nieto; Christopher I Li; David Gozal; Timothy Thornton; Sonnah Barrie; Amanda I Phipps
Journal:  Cancer Epidemiol       Date:  2021-11-17       Impact factor: 2.984

3.  MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets.

Authors:  Samuel Swearson; Aseel O Rataan; Steven Eliason; Brad A Amendt; Yousef Zakharia; Aliasger K Salem; Thai Ho; Youcef M Rustum
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

Review 4.  Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy.

Authors:  M S Petronek; J M Stolwijk; S D Murray; E J Steinbach; Y Zakharia; G R Buettner; D R Spitz; B G Allen
Journal:  Redox Biol       Date:  2021-01-16       Impact factor: 10.787

Review 5.  Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.

Authors:  Yousef Zakharia; Arup Bhattacharya; Youcef M Rustum
Journal:  Oncotarget       Date:  2018-01-23

6.  Intermittent hypoxia increases kidney tumor vascularization in a murine model of sleep apnea.

Authors:  Antoni Vilaseca; Noelia Campillo; Marta Torres; Mireia Musquera; David Gozal; Josep M Montserrat; Antonio Alcaraz; Karim A Touijer; Ramon Farré; Isaac Almendros
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

7.  Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.

Authors:  Youcef M Rustum; Sreenivasulu Chintala; Farukh A Durrani; Arup Bhattacharya
Journal:  Int J Mol Sci       Date:  2018-10-29       Impact factor: 5.923

Review 8.  Understanding the Redox Biology of Selenium in the Search of Targeted Cancer Therapies.

Authors:  Jeffrey M Stolwijk; Rohan Garje; Jessica C Sieren; Garry R Buettner; Yousef Zakharia
Journal:  Antioxidants (Basel)       Date:  2020-05-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.